文献速递白血病MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

维奈克拉治疗CLL中克隆性造血、髓系疾病与BAX突变髓系生成

Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.
PubMed 文献 · Blood · 2022-01-01

该研究纳入89例接受长期维奈克拉治疗的CLL患者(87例复发/难治),中位随访75个月,28%出现持续≥4个月且与CLL无关的细胞减少,其中80%存在克隆性造血,10例发生治疗相关髓系肿瘤。在骨髓CLL负荷低或无的患者中,32%检出BAX突变,体外实验显示BAX突变导致对维奈克拉杀伤抵抗。

要点

  • 长期维奈克拉治疗CLL可出现持续细胞减少,需警惕克隆性造血及治疗相关髓系肿瘤。
  • 治疗相关髓系肿瘤仅见于既往接受氟达拉滨-烷化剂联合治疗者,5年累积发生率10.4%。
  • BAX突变在髓系克隆中常见,可致维奈克拉抵抗,但与治疗相关髓系肿瘤无关。

核心结论

  • 长期维奈克拉治疗CLL可伴随克隆性造血和髓系疾病,BAX突变介导髓系细胞对维奈克拉的抵抗。

研究设计与样本

  • 回顾性/观察性研究,纳入89例接受长期持续维奈克拉治疗的CLL患者(87例复发/难治),中位随访75个月(范围21-98)。

主要发现

  • 25例(28%)出现持续≥4个月且与CLL无关的细胞减少(中性粒细胞减少、血小板减少、贫血中至少1种)。
  • 上述25例中20例(80%)存在克隆性造血,包括10例治疗相关髓系肿瘤(t-MNs)。
  • t-MNs仅见于既往暴露于氟达拉滨-烷化剂联合治疗的患者,维奈克拉开始后5年累积发生率为10.4%。
  • 在骨髓CLL负荷无或极少的41例患者中,32%(13/41)检出BAX突变。
  • 细胞实验显示C端BAX突变体阻止BAX定位于线粒体外膜,导致对维奈克拉杀伤抵抗。

关键数值与推荐

  • 持续细胞减少定义为中性粒细胞减少、血小板减少或贫血中至少1种持续≥4个月且与CLL无关。
  • t-MNs 5年累积发生率10.4%(维奈克拉开始后),与既往暴露于氟达拉滨-烷化剂联合治疗但未用维奈克拉的患者报告率一致。
  • BAX突变在骨髓CLL负荷无或极少的患者中检出率为32%(13/41)。

临床怎么用

  • 长期维奈克拉治疗CLL时应监测持续细胞减少,并评估克隆性造血及髓系肿瘤。
  • 既往接受氟达拉滨-烷化剂联合治疗者,维奈克拉治疗后需警惕治疗相关髓系肿瘤。
  • BAX突变提示髓系细胞对维奈克拉抵抗,但当前数据不支持其作为t-MNs的预测标志。

局限性

  • 样本量较小(89例),部分分析基于41例骨髓CLL负荷低或无的患者。
  • 为观察性研究,t-MNs发生率需更大样本验证。
  • BAX突变与t-MNs无关联的结论基于有限事件数。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The BCL2 inhibitor venetoclax has established therapeutic roles in chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). As BCL2 is an important determinant of survival of both myeloid progenitor and B cells, we investigated whether clinical and molecular abnormalities arise in the myeloid compartment during long-term continuous venetoclax treatment of CLL in 89 patients (87 with relapsed/refractory CLL). Over a median follow-up of 75 (range 21-98) months, persistent cytopenias (≥1 of neutropenia, thrombocytopenia, anemia) lasting ≥4 months and unrelated to CLL occurred in 25 patients (28%). Of these patients, 20 (80%) displayed clonal hematopoiesis, including 10 with therapy-related myeloid neoplasms (t-MNs). t-MNs occurred exclusively in patients previously exposed to fludarabine-alkylator combination therapy with a cumulative 5-year incidence of 10.4% after venetoclax initiation, consistent with rates reported for patients exposed to fludarabine-alkylator combination therapy without venetoclax. To determine whether the altered myelopoiesis reflected the acquisition of mutations, we analyzed samples from patients with no or minimal bone marrow CLL burden (n = 41). Mutations in the apoptosis effector BAX were identified in 32% (13/41). In cellular assays, C-terminal BAX mutants abrogated outer mitochondrial membrane localization of BAX and engendered resistance to venetoclax killing. BAX-mutated clonal hematopoiesis occurred independently of prior fludarabine-alkylator combination therapy exposure and was not associated with t-MNs. Single-cell sequencing revealed clonal co-occurrence of mutations in BAX with DNMT3A or ASXL1. We also observed simultaneous BCL2 mutations within CLL cells and BAX mutations in the myeloid compartment of the same patients, indicating lineage-specific adaptation to venetoclax therapy.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Blombery P, Lew TE, Dengler MA, et al. Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL. Blood. 2022. PMID: 34469514. doi:10.1182/blood.2021012775

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。